<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJS</journal-id><journal-title-group><journal-title>Open Journal of Statistics</journal-title></journal-title-group><issn pub-type="epub">2161-718X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojs.2018.84042</article-id><article-id pub-id-type="publisher-id">OJS-86068</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Physics&amp;Mathematics</subject></subj-group></article-categories><title-group><article-title>
 
 
  Analysis of Influencing Factors on Survival Time of Patients with Heart Failure
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jianwei</surname><given-names>Sheng</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Xiyuan</surname><given-names>Qian</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tong</surname><given-names>Ruan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>School of Information Science and Engineering, East China University of Science and Technology, Shanghai, China</addr-line></aff><aff id="aff1"><addr-line>School of Science, East China University of Science and Technology, Shanghai, China</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>xyqian@ecust.edu.cn(XQ)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>07</month><year>2018</year></pub-date><volume>08</volume><issue>04</issue><fpage>651</fpage><lpage>659</lpage><history><date date-type="received"><day>6,</day>	<month>May</month>	<year>2018</year></date><date date-type="rev-recd"><day>16,</day>	<month>July</month>	<year>2018</year>	</date><date date-type="accepted"><day>19,</day>	<month>July</month>	<year>2018</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  To explore the influencing factors of survival time of patients with heart failure, a total of 1789 patients with heart failure were collected from Shanghai Shuguang
   
  Hospital. The Cox proportional hazards model and the mixed effects Cox model were
   
  used to analyze the factors on survival time of patients. The results of Cox proportional hazards model showed that age (RR = 1.32), hypertension (RR = 0.67), ARB (RR = 0.55), diuretic (RR = 1.48) and antiplatelet (RR = 0.53) have significant impacts on the survival time of patients. The results of mixed effects Cox model showed that age (RR = 1.16), hypertension (RR = 0.61), lung infection (RR = 1.43), ARB (RR = 0.64), β-blockers (RR = 0.77) and antiplatelet (RR = 0.69) have a significant impact on the survival time of patients. The results are consistent with the covariates age, hypertension, ARB and antiplatelet but inconsistent with the covariates lung infection
   
  and β-blockers.
 
</p></abstract><kwd-group><kwd>Heart Failure</kwd><kwd> Survival Analysis</kwd><kwd> Longitudinal Data</kwd><kwd> Mixed Effects Cox Model</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Heart failure is a syndrome with symptoms and signs caused by cardiac dysfunction, resulting in reduced longevity [<xref ref-type="bibr" rid="scirp.86068-ref1">1</xref>] . The prevalence of heart failure in western countries is 1% - 2% of the adult population and 5 - 10 per 1000 population per year, respectively [<xref ref-type="bibr" rid="scirp.86068-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.86068-ref3">3</xref>] . In China, the prevalence of heart failure in Chinese population aged 35 - 74 is 0.9% and the population significantly increases with age [<xref ref-type="bibr" rid="scirp.86068-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.86068-ref5">5</xref>] . With the acceleration of population aging in China, it is foreseeable that the burden caused by heart failure will become heavier in the near future. So it is important to study and analyze the influencing factors of the survival time of patients with heart failure.</p><p>In medical research, follow-up is the common way to study the law of things; for instance: study the efficacy of a drug, study the survival time after surgery, study the lifetime of a medical device [<xref ref-type="bibr" rid="scirp.86068-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.86068-ref7">7</xref>] . The common ground of the above studies is that it will take some time to trace the research objects, which was called the survival time in statistics. The study of the distribution and influencing factors of survival time is the so-called survival analysis [<xref ref-type="bibr" rid="scirp.86068-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.86068-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.86068-ref10">10</xref>] . Proportional hazard regression model has become the most common used procedure for modeling the relationship of covariates to a survival or other censored outcome since this model was proposed by D.R. Cox in 1972 [<xref ref-type="bibr" rid="scirp.86068-ref11">11</xref>] . In clinical practice, many studies collect both longitudinal data [<xref ref-type="bibr" rid="scirp.86068-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.86068-ref13">13</xref>] (longitudinal data are data in which a response variable is measured at different time points over time) and survival-time data. In this paper, Cox proportional hazards model was used to model the survival-time data and mixed effects Cox model [<xref ref-type="bibr" rid="scirp.86068-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.86068-ref15">15</xref>] was used to model the survival-time and longitudinal data.</p></sec><sec id="s2"><title>2. Models</title><sec id="s2_1"><title>2.1. Cox Proportional Hazards Model</title><p>The Cox proportional hazards model was proposed by British statistician D.R. Cox in 1972, which has been widely applied to analyze the effect of exposure and other covariates on patient’s survival. The Cox model specifies the hazard for individual i as:</p><p>λ i ( t ) = λ 0 ( t ) exp ( β 1 X i 1 + β 2 X i 2 + ⋯ + β p X i p ) = λ 0 ( t ) exp ( X i ( t ) β ) (1)</p><p>where β = ( β 1 , β 2 , ⋯ β p ) T is a p &#215; 1 column vector of coefficients, X i = ( X i 1 , X i 2 , ⋯ , X i p ) is a 1 &#215; p vector of covariates for subject i, and λ 0 ( t ) is an unspecified nonnegative function of time called the baseline hazard, describing how the risk of event per time unit changes over time at baseline levels of covariates. Since the hazard ratio for two subjects with fixed covariate vectors X i and X j</p><p>λ i ( t ) λ j ( t ) = λ 0 ( t ) exp ( X i β ) λ 0 ( t ) exp ( X j β ) = exp ( ( X i − X j ) β ) (2)</p><p>is constant over time, the model is called proportional hazards model.</p><p>Let the event be observed to have occurred with subject i at time t i . The probability that happened can be written as</p><p>L i ( β ) = λ ( t i | X i ) ∑ : t j ≥ t i λ ( t i | X j ) = θ i ∑ : t j ≥ t i θ j (3)</p><p>where θ j = exp ( X j β ) and the summation is over the set of subjects j who is still under observation at time t i , the set is called risk set and denoted by R ( t i ) , this is the partial likelihood for subject i. So taking the product of Equation (3) yields the partial likelihood function:</p><p>P L ( β ) = ∏ i = 1 n [ exp ( X i β ) ∑ j ∈ R ( t i ) exp ( X j β ) ] δ i (4)</p><p>where δ i is 1 if the event is happened to subject i and 0 otherwise.</p></sec><sec id="s2_2"><title>2.2. Mixed Effects Cox Model</title><p>In clinical practice, some subjects may be observed more than once during the time from first hospitalization to death. The number of hospitalizations and the days between two hospitalizations varies from patient to patient in the heart failure set. The Cox proportional hazards model only uses the survival-time data, which inevitably lose some useful information. The data obtained from multiple measurements of a series of experimental individuals over time are called longitudinal data. More precisely, suppose there are m individuals in an experiment where each individual is measured over time. Y i 1 , Y i 2 , ⋯ Y i n i , i = 1 , ⋯ , m are the measured data for the individual i at time t i 1 &lt; t i 2 &lt; ⋯ &lt; t i n i , then { Y i k : 1 ≤ k ≤ n i , 1 ≤ i ≤ m } is called longitudinal data, which is also called panel data in econometrics [<xref ref-type="bibr" rid="scirp.86068-ref16">16</xref>] . This type of data is different from cross-section data and time series data. The linear mixed effects model is a common model to dealing with the longitudinal data [<xref ref-type="bibr" rid="scirp.86068-ref17">17</xref>] . It adds individual difference as random effects into the regression model. These random effects describe how every object’s measurement changes over time and reflect the internal structure of the longitudinal data. In matrix notation a mixed model can be represented as:</p><p>Y = X T β + Z T b + ε , b ∼ N ( 0 , Σ ) (5)</p><p>where and are the design matrices for the fixed and random effects respectively, β is the vector of fixed-effects coefficients and b is the vector of random effects coefficients and ε is the random error. The random effects distribution is modeled as Gaussian with mean zero and a variance matrix Σ . Combining Equation (1) and (3) yields the mixed effects Cox model:</p><p>λ ( t ) = λ 0 ( t ) exp ( X T β + Z T b ) , b ∼ N ( 0 , Σ ) (6)</p><p>Coefficients can be estimated based on the partial likelihood:</p><p>ln [ P L ( β , b ) ] = ∑ i = 1 n ∫ 0 ∞ { Y i ( t ) η i ( t ) − ln [ ∑ j Y j ( t ) exp ( η j ( t ) ) ] } d t (7)</p><p>where η i ( t ) = X i ( t ) β + Z i ( t ) b is the linear score for subject i at time t and Y i ( t ) = 1 if subject i is still under observation at time t and 0 otherwise [<xref ref-type="bibr" rid="scirp.86068-ref18">18</xref>] [<xref ref-type="bibr" rid="scirp.86068-ref19">19</xref>] .</p></sec></sec><sec id="s3"><title>3. Data</title><p>We collected patient basic information, laboratory information, medical records, doctor’s advice information and other information from Shanghai Shuguang Hospital database during January 1, 2003 to December 31, 2013. The start point of survival analysis is the first time in hospital date and the end point is the last time out of hospital date or the date of death or the end date of the study. According to the guidance of the doctor formed the heart failure dataset used in this paper. This dataset contains data from 1789 patients with heart failure, for a total of 8332 observations and 23 covariates. See <xref ref-type="table" rid="table1">Table 1</xref> for details.</p><p>Most are categorical variables, but age is a multi-variable. Its distribution is shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>.</p><p>Statistics for other binary variables are shown in <xref ref-type="table" rid="table2">Table 2</xref>.</p></sec><sec id="s4"><title>4. Results</title><p>Firstly, we use the Cox proportional hazards to model the survival-time data with all covariates. The results are shown in <xref ref-type="table" rid="table3">Table 3</xref>.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Variables description in heart failure dataset</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >variables</th><th align="center" valign="middle" >Description</th><th align="center" valign="middle" >Data Type</th></tr></thead><tr><td align="center" valign="middle" >Id</td><td align="center" valign="middle" >Patient id</td><td align="center" valign="middle" >Categorical</td></tr><tr><td align="center" valign="middle" >num</td><td align="center" valign="middle" >Hospitalization number of patients</td><td align="center" valign="middle" >Categorical</td></tr><tr><td align="center" valign="middle" >Status</td><td align="center" valign="middle" >1 = dead, 0 = alive</td><td align="center" valign="middle" >Binary</td></tr><tr><td align="center" valign="middle" >day</td><td align="center" valign="middle" >Number of days between first hospitalization and death or last out of hospital</td><td align="center" valign="middle" >Numeric</td></tr><tr><td align="center" valign="middle" >days</td><td align="center" valign="middle" >Number of days between first hospitalization and this in hospitalization date</td><td align="center" valign="middle" >Numeric</td></tr><tr><td align="center" valign="middle" >age</td><td align="center" valign="middle" >1 = (0,40], 2 = (41,50], 3 =(51,60], 4 = (61,70], 5 = (71,80], 6 = (81,90], 7 = (91,100]</td><td align="center" valign="middle" >Multi-category</td></tr><tr><td align="center" valign="middle" >sex</td><td align="center" valign="middle" >1 = male, 0 = female</td><td align="center" valign="middle" >Binary</td></tr><tr><td align="center" valign="middle" >Chin_Med</td><td align="center" valign="middle" >Whether used Chinese Medicine? 1 = yes, 0 = no</td><td align="center" valign="middle" >Binary</td></tr><tr><td align="center" valign="middle" >RBC</td><td align="center" valign="middle" >Red blood cells in mg/ml</td><td align="center" valign="middle" >Numeric</td></tr><tr><td align="center" valign="middle" >HGB</td><td align="center" valign="middle" >Hemoglobin in mg/ml</td><td align="center" valign="middle" >Numeric</td></tr><tr><td align="center" valign="middle" >hypertension</td><td align="center" valign="middle" >Presence of hypertension, 1 = yes, 0 = no</td><td align="center" valign="middle" >Binary</td></tr><tr><td align="center" valign="middle" >coronary</td><td align="center" valign="middle" >Presence of coronary heart disease, 1 = yes, 0 = no</td><td align="center" valign="middle" >Binary</td></tr><tr><td align="center" valign="middle" >diabetes</td><td align="center" valign="middle" >Presence of diabetes, 1 = yes, 0 = no</td><td align="center" valign="middle" >Binary</td></tr><tr><td align="center" valign="middle" >lung_infe</td><td align="center" valign="middle" >Presence of lung infection, 1 = yes, 0 = no</td><td align="center" valign="middle" >Binary</td></tr><tr><td align="center" valign="middle" >bronchitis</td><td align="center" valign="middle" >Presence of chronic bronchitis, 1 = yes, 0 = no</td><td align="center" valign="middle" >Binary</td></tr><tr><td align="center" valign="middle" >ACEI</td><td align="center" valign="middle" >Whether used angiotensin converting enzyme inhibitors? 1 = yes, 0 = no</td><td align="center" valign="middle" >Binary</td></tr><tr><td align="center" valign="middle" >ARA</td><td align="center" valign="middle" >Whether used aldosterone receptor antagonists? 1 = yes, 0 = no</td><td align="center" valign="middle" >Binary</td></tr><tr><td align="center" valign="middle" >ARB</td><td align="center" valign="middle" >Whether used angiotensin receptor blocker? 1 = yes, 0 = no</td><td align="center" valign="middle" >Binary</td></tr><tr><td align="center" valign="middle" >Blocker</td><td align="center" valign="middle" >Whether used β blocker? 1 = yes, 0 = no</td><td align="center" valign="middle" >Binary</td></tr><tr><td align="center" valign="middle" >diuretic</td><td align="center" valign="middle" >Whether used Diuretic? 1 = yes, 0 = no</td><td align="center" valign="middle" >Binary</td></tr><tr><td align="center" valign="middle" >digitalis</td><td align="center" valign="middle" >Whether used digitalis? 1 = yes, 0 = no</td><td align="center" valign="middle" >Binary</td></tr><tr><td align="center" valign="middle" >anti-platelet</td><td align="center" valign="middle" >Whether used anti-platelet? 1 = yes, 0 = no</td><td align="center" valign="middle" >Binary</td></tr><tr><td align="center" valign="middle" >nitrate</td><td align="center" valign="middle" >Whether used nitrate? 1 = yes, 0 = no</td><td align="center" valign="middle" >Binary</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Statistics for binary variable in hear failure set (total = 1789)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >variables</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >N (%)</th></tr></thead><tr><td align="center" valign="middle"  rowspan="2"  >status</td><td align="center" valign="middle" >alive</td><td align="center" valign="middle" >1531 (85.6)</td></tr><tr><td align="center" valign="middle" >death</td><td align="center" valign="middle" >258 (14.4)</td></tr><tr><td align="center" valign="middle" >sex</td><td align="center" valign="middle" >male female</td><td align="center" valign="middle" >955 (53.3) 834 (46.7)</td></tr><tr><td align="center" valign="middle" >chin_med</td><td align="center" valign="middle" >yes no</td><td align="center" valign="middle" >1337 (74.7) 834 (25.3)</td></tr><tr><td align="center" valign="middle" >coronary</td><td align="center" valign="middle" >yes no</td><td align="center" valign="middle" >501 (28) 1288 (72)</td></tr><tr><td align="center" valign="middle" >hypertension</td><td align="center" valign="middle" >yes no</td><td align="center" valign="middle" >1119 (62.6) 670 (37.4)</td></tr><tr><td align="center" valign="middle" >diabetes</td><td align="center" valign="middle" >yes no</td><td align="center" valign="middle" >498 (27.8) 1291 (72.2)</td></tr><tr><td align="center" valign="middle" >lung_infe</td><td align="center" valign="middle" >yes no</td><td align="center" valign="middle" >215 (12) 1574 (88)</td></tr><tr><td align="center" valign="middle" >bronchitis</td><td align="center" valign="middle" >yes no</td><td align="center" valign="middle" >246 (13.7) 1543 (86.3)</td></tr><tr><td align="center" valign="middle" >ACEI</td><td align="center" valign="middle" >yes no</td><td align="center" valign="middle" >392 (21.9) 1937 (78.1)</td></tr><tr><td align="center" valign="middle" >ARA</td><td align="center" valign="middle" >yes no</td><td align="center" valign="middle" >373 (20.8) 1416 (79.2)</td></tr><tr><td align="center" valign="middle" >ARB</td><td align="center" valign="middle" >yes no</td><td align="center" valign="middle" >361 (20.2) 1428 (79.8)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >Blocker</td><td align="center" valign="middle" >yes</td><td align="center" valign="middle" >800 (44.7)</td></tr><tr><td align="center" valign="middle" >no</td><td align="center" valign="middle" >989 (55.3)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >diuretic</td><td align="center" valign="middle" >yes</td><td align="center" valign="middle" >383 (21.4)</td></tr><tr><td align="center" valign="middle" >no</td><td align="center" valign="middle" >1406 (78.6)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >digitalis</td><td align="center" valign="middle" >yes</td><td align="center" valign="middle" >1117 (62.4)</td></tr><tr><td align="center" valign="middle" >no</td><td align="center" valign="middle" >672 (37.6)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >anti-platelet</td><td align="center" valign="middle" >yes</td><td align="center" valign="middle" >709 (39.6)</td></tr><tr><td align="center" valign="middle" >no</td><td align="center" valign="middle" >1080 (60.4)</td></tr><tr><td align="center" valign="middle"  rowspan="2"  >nitrate</td><td align="center" valign="middle" >yes</td><td align="center" valign="middle" >892 (49.9)</td></tr><tr><td align="center" valign="middle" >no</td><td align="center" valign="middle" >897 (50.1)</td></tr></tbody></table></table-wrap><p>Secondly, we use the mixed effects Cox model to model the survival-time data and longitudinal data with all the covariates and variable day as the covariate for random effects. The results are shown in <xref ref-type="table" rid="table4">Table 4</xref>.</p></sec><sec id="s5"><title>5. Conclusions</title><p>Cox proportional hazards model showed that age, hypertension, ARB, diuretics and antiplatelet have a statistically significant effect on the survival time of patients. Age (RR = 1.32) and diuretic (RR = 1.48) were risk factors. Hypertension (RR = 0.67), ARB (RR = 0.55) and antiplatelet (RR = 0.53) were protective factors. The mixed effects Cox model showed that age, hypertension, lung infection, ARB, β-blockers, and antiplatelet have statistically significant effects on the survival time of patients. Age (RR = 1.16) and lung infection (RR = 1.43) were risk</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Result of Cox proportional hazards model with all covariates</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >variables</th><th align="center" valign="middle" >coef</th><th align="center" valign="middle" >RR</th><th align="center" valign="middle" >Se (coef)</th><th align="center" valign="middle" >z</th><th align="center" valign="middle" >p-value</th></tr></thead><tr><td align="center" valign="middle" >sex</td><td align="center" valign="middle" >0.222649</td><td align="center" valign="middle" >1.249383</td><td align="center" valign="middle" >0.178811</td><td align="center" valign="middle" >1.245</td><td align="center" valign="middle" >0.21307</td></tr><tr><td align="center" valign="middle" >age</td><td align="center" valign="middle" >0.275551</td><td align="center" valign="middle" >1.317256</td><td align="center" valign="middle" >0.097916</td><td align="center" valign="middle" >2.814</td><td align="center" valign="middle" >0.00489</td></tr><tr><td align="center" valign="middle" >Chin_med</td><td align="center" valign="middle" >−0.31796</td><td align="center" valign="middle" >0.727633</td><td align="center" valign="middle" >0.200295</td><td align="center" valign="middle" >−1.587</td><td align="center" valign="middle" >0.11241</td></tr><tr><td align="center" valign="middle" >RBC</td><td align="center" valign="middle" >−0.1807</td><td align="center" valign="middle" >0.834684</td><td align="center" valign="middle" >0.244466</td><td align="center" valign="middle" >−0.739</td><td align="center" valign="middle" >0.4598</td></tr><tr><td align="center" valign="middle" >HGB</td><td align="center" valign="middle" >−0.00859</td><td align="center" valign="middle" >0.991447</td><td align="center" valign="middle" >0.007816</td><td align="center" valign="middle" >−1.099</td><td align="center" valign="middle" >0.27175</td></tr><tr><td align="center" valign="middle" >hypertension</td><td align="center" valign="middle" >−0.40512</td><td align="center" valign="middle" >0.6669</td><td align="center" valign="middle" >0.196386</td><td align="center" valign="middle" >−2.063</td><td align="center" valign="middle" >0.03913</td></tr><tr><td align="center" valign="middle" >coronary</td><td align="center" valign="middle" >0.029494</td><td align="center" valign="middle" >1.029934</td><td align="center" valign="middle" >0.203818</td><td align="center" valign="middle" >0.145</td><td align="center" valign="middle" >0.88494</td></tr><tr><td align="center" valign="middle" >diabetes</td><td align="center" valign="middle" >−0.01215</td><td align="center" valign="middle" >0.987926</td><td align="center" valign="middle" >0.22145</td><td align="center" valign="middle" >−0.055</td><td align="center" valign="middle" >0.95625</td></tr><tr><td align="center" valign="middle" >lung_infe</td><td align="center" valign="middle" >−0.26373</td><td align="center" valign="middle" >0.768185</td><td align="center" valign="middle" >0.307327</td><td align="center" valign="middle" >−0.858</td><td align="center" valign="middle" >0.39082</td></tr><tr><td align="center" valign="middle" >bronchitis</td><td align="center" valign="middle" >0.218949</td><td align="center" valign="middle" >1.244768</td><td align="center" valign="middle" >0.21796</td><td align="center" valign="middle" >1.005</td><td align="center" valign="middle" >0.31512</td></tr><tr><td align="center" valign="middle" >ACEI</td><td align="center" valign="middle" >−0.24764</td><td align="center" valign="middle" >0.780638</td><td align="center" valign="middle" >0.240374</td><td align="center" valign="middle" >−1.03</td><td align="center" valign="middle" >0.3029</td></tr><tr><td align="center" valign="middle" >ARA</td><td align="center" valign="middle" >−0.27402</td><td align="center" valign="middle" >0.760313</td><td align="center" valign="middle" >0.21431</td><td align="center" valign="middle" >−1.279</td><td align="center" valign="middle" >0.20102</td></tr><tr><td align="center" valign="middle" >ARB</td><td align="center" valign="middle" >−0.60086</td><td align="center" valign="middle" >0.54834</td><td align="center" valign="middle" >0.266228</td><td align="center" valign="middle" >−2.257</td><td align="center" valign="middle" >0.02401</td></tr><tr><td align="center" valign="middle" >Bblocker</td><td align="center" valign="middle" >−0.19269</td><td align="center" valign="middle" >0.824737</td><td align="center" valign="middle" >0.186844</td><td align="center" valign="middle" >−1.031</td><td align="center" valign="middle" >0.3024</td></tr><tr><td align="center" valign="middle" >diuretic</td><td align="center" valign="middle" >0.389164</td><td align="center" valign="middle" >1.475747</td><td align="center" valign="middle" >0.191756</td><td align="center" valign="middle" >2.029</td><td align="center" valign="middle" >0.04241</td></tr><tr><td align="center" valign="middle" >digitalis</td><td align="center" valign="middle" >0.305065</td><td align="center" valign="middle" >1.356714</td><td align="center" valign="middle" >0.184673</td><td align="center" valign="middle" >1.652</td><td align="center" valign="middle" >0.09855</td></tr><tr><td align="center" valign="middle" >anti-platelet</td><td align="center" valign="middle" >−0.64137</td><td align="center" valign="middle" >0.526573</td><td align="center" valign="middle" >0.206546</td><td align="center" valign="middle" >−3.105</td><td align="center" valign="middle" >0.0019</td></tr><tr><td align="center" valign="middle" >nitrate</td><td align="center" valign="middle" >0.319543</td><td align="center" valign="middle" >1.376498</td><td align="center" valign="middle" >0.173849</td><td align="center" valign="middle" >1.838</td><td align="center" valign="middle" >0.06605</td></tr></tbody></table></table-wrap><p>*coef is the estimation of the coefficients; RR is relative risk; Se (coef) is the standard error of the estimation.</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Results of mixed effects Cox model</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >variables</th><th align="center" valign="middle" >coef</th><th align="center" valign="middle" >RR</th><th align="center" valign="middle" >Se (coef)</th><th align="center" valign="middle" >z</th><th align="center" valign="middle" >p-value</th></tr></thead><tr><td align="center" valign="middle" >sex</td><td align="center" valign="middle" >0.301405</td><td align="center" valign="middle" >1.351757</td><td align="center" valign="middle" >0.161594</td><td align="center" valign="middle" >1.87</td><td align="center" valign="middle" >0.062</td></tr><tr><td align="center" valign="middle" >age</td><td align="center" valign="middle" >0.144165</td><td align="center" valign="middle" >1.155074</td><td align="center" valign="middle" >0.067629</td><td align="center" valign="middle" >2.13</td><td align="center" valign="middle" >0.033</td></tr><tr><td align="center" valign="middle" >Chin_med</td><td align="center" valign="middle" >−0.02249</td><td align="center" valign="middle" >0.977757</td><td align="center" valign="middle" >0.082878</td><td align="center" valign="middle" >−0.27</td><td align="center" valign="middle" >0.79</td></tr><tr><td align="center" valign="middle" >RBC</td><td align="center" valign="middle" >−0.1126</td><td align="center" valign="middle" >0.893511</td><td align="center" valign="middle" >0.169517</td><td align="center" valign="middle" >−0.66</td><td align="center" valign="middle" >0.51</td></tr><tr><td align="center" valign="middle" >HGB</td><td align="center" valign="middle" >−0.01085</td><td align="center" valign="middle" >0.989209</td><td align="center" valign="middle" >0.005333</td><td align="center" valign="middle" >−2.03</td><td align="center" valign="middle" >0.042</td></tr><tr><td align="center" valign="middle" >hypertension</td><td align="center" valign="middle" >−0.49125</td><td align="center" valign="middle" >0.611863</td><td align="center" valign="middle" >0.127701</td><td align="center" valign="middle" >−3.85</td><td align="center" valign="middle" >0.00012</td></tr><tr><td align="center" valign="middle" >coronary</td><td align="center" valign="middle" >−0.1687</td><td align="center" valign="middle" >0.844765</td><td align="center" valign="middle" >0.140132</td><td align="center" valign="middle" >−1.2</td><td align="center" valign="middle" >0.23</td></tr><tr><td align="center" valign="middle" >diabetes</td><td align="center" valign="middle" >−0.23967</td><td align="center" valign="middle" >0.786885</td><td align="center" valign="middle" >0.161708</td><td align="center" valign="middle" >−1.48</td><td align="center" valign="middle" >0.14</td></tr><tr><td align="center" valign="middle" >lung_infe</td><td align="center" valign="middle" >0.356836</td><td align="center" valign="middle" >1.428802</td><td align="center" valign="middle" >0.124253</td><td align="center" valign="middle" >2.87</td><td align="center" valign="middle" >0.0041</td></tr><tr><td align="center" valign="middle" >bronchitis</td><td align="center" valign="middle" >0.250458</td><td align="center" valign="middle" >1.284613</td><td align="center" valign="middle" >0.148653</td><td align="center" valign="middle" >1.68</td><td align="center" valign="middle" >0.092</td></tr><tr><td align="center" valign="middle" >ACEI</td><td align="center" valign="middle" >−0.32509</td><td align="center" valign="middle" >0.722463</td><td align="center" valign="middle" >0.154382</td><td align="center" valign="middle" >−2.11</td><td align="center" valign="middle" >0.035</td></tr><tr><td align="center" valign="middle" >ARA</td><td align="center" valign="middle" >0.069231</td><td align="center" valign="middle" >1.071684</td><td align="center" valign="middle" >0.123429</td><td align="center" valign="middle" >0.56</td><td align="center" valign="middle" >0.57</td></tr><tr><td align="center" valign="middle" >ARB</td><td align="center" valign="middle" >−0.44209</td><td align="center" valign="middle" >0.642691</td><td align="center" valign="middle" >0.122451</td><td align="center" valign="middle" >−3.61</td><td align="center" valign="middle" >0.00031</td></tr><tr><td align="center" valign="middle" >Bblocker</td><td align="center" valign="middle" >−0.26293</td><td align="center" valign="middle" >0.768796</td><td align="center" valign="middle" >0.089191</td><td align="center" valign="middle" >−2.95</td><td align="center" valign="middle" >0.0032</td></tr><tr><td align="center" valign="middle" >diuretic</td><td align="center" valign="middle" >0.115389</td><td align="center" valign="middle" >1.12231</td><td align="center" valign="middle" >0.104295</td><td align="center" valign="middle" >1.11</td><td align="center" valign="middle" >0.27</td></tr><tr><td align="center" valign="middle" >digitalis</td><td align="center" valign="middle" >0.037052</td><td align="center" valign="middle" >1.037747</td><td align="center" valign="middle" >0.081806</td><td align="center" valign="middle" >0.45</td><td align="center" valign="middle" >0.65</td></tr><tr><td align="center" valign="middle" >anti-platelet</td><td align="center" valign="middle" >−0.3711</td><td align="center" valign="middle" >0.689975</td><td align="center" valign="middle" >0.101789</td><td align="center" valign="middle" >−3.65</td><td align="center" valign="middle" >0.00027</td></tr><tr><td align="center" valign="middle" >nitrate</td><td align="center" valign="middle" >0.029271</td><td align="center" valign="middle" >1.029703</td><td align="center" valign="middle" >0.086633</td><td align="center" valign="middle" >0.34</td><td align="center" valign="middle" >0.74</td></tr></tbody></table></table-wrap><p>factors; hypertension (RR = 0.61), ARB (RR = 0.64), β blockers (RR = 0.77) and antiplatelet (RR = 0.69) were protective factors. Results of the two models are consistent with the covariates age, hypertension, ARB and antiplatelet. Further, age was risk factor, namely the older has lower survival rate. Hypertension, ARB, and antiplatelet were protective factors, namely patients with hypertension have higher survival rates than those without hypertension; patients who used ARBs had higher survival rates than unused patients; patients who used antiplatelet drugs had higher survival rates than those who did not. Survival distributions by these covariates are shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p><p>The difference is that there are another two covariates which have significantly effect on the survival rate in the mixed effects Cox model: one was risk factor lung infection (RR = 1.43), and the other was protective factor β blocker (RR = 0.67). In addition, the protective factor diuretic in the Cox proportional hazards model became insignificant in the mixed effects Cox model, which shows that the effect of diuretics on survival rate gradually reduces.</p></sec><sec id="s6"><title>Acknowledgements</title><p>This work was partially supported by The National High-Tech R&amp;D Program of China (863 Program) under Grant No. 2015AA020107.</p></sec><sec id="s7"><title>Cite this paper</title><p>Sheng, J.W., Qian, X.Y. and Ruan, T. (2018) Analysis of Influencing Factors on Survival Time of Patients with Heart Failure. Open Journal of Statistics, 8, 651-659. https://doi.org/10.4236/ojs.2018.84042</p></sec></body><back><ref-list><title>References</title><ref id="scirp.86068-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Mosterd, A. and Hoes, A.W. (2007) Clinical Epidemiology of Heart Failure. Heart, 93, 1137-1146. https://doi.org/10.1136/hrt.2003.025270</mixed-citation></ref><ref id="scirp.86068-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">McMurray, J.J., Adamopoulos, S., Anker, S.D., et al. (2012) ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal, 33, 1787-1146.</mixed-citation></ref><ref id="scirp.86068-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Cowie, M.R., Wood, D.A., Coats, A.J., et al. (1999) Incidence an Aetiology of Heart Failure: A Population-Based Study. European Heart Journal, 20, 421-428.  
https://doi.org/10.1053/euhj.1998.1280</mixed-citation></ref><ref id="scirp.86068-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Guo, Y., Zhao, D. and Liu, J. (2015) Epidemiological Study of Heart Failure in China. Cardiovascular Innovations and Applications, 1, 47-55.  
https://doi.org/10.15212/CVIA.2015.0003</mixed-citation></ref><ref id="scirp.86068-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Gu, D.F., Huang, G.Y., He, J., et al. (2003) Investigation of Prevalence and Distribution Feature of Chronic Heart Failure in Chinese Adult Population. Chinese Journal Cardio, 1, 3-6.</mixed-citation></ref><ref id="scirp.86068-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Bland, J.M. (2000) An Introduction to Medical Statistics. 3rd Edition, Oxford University Press, New York.</mixed-citation></ref><ref id="scirp.86068-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kirkwood, B.R. and Sterne, J.C. (2003) Essential Medical Statistics. 2nd Edition, Blackwell Publishers, Malden.</mixed-citation></ref><ref id="scirp.86068-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Klein, J.P. (2013) Handbook of Survival Analysis. CRC Press, Boca Raton.</mixed-citation></ref><ref id="scirp.86068-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lawless, J.F. (2003) Statistical Models and Methods for Lifetime Data. 2nd Edition, John Wiley and Sons, New York.</mixed-citation></ref><ref id="scirp.86068-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Kalbfleisch, J.D. and Prentice, R.L. (2002) The Statistical Analysis of Failure Time Data. John Wiley and Sons, New York. https://doi.org/10.1002/9781118032985</mixed-citation></ref><ref id="scirp.86068-ref11"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cox</surname><given-names> D.R. </given-names></name>,<etal>et al</etal>. (<year>1972</year>)<article-title>Regression Models and Lifetables (with Discussion)</article-title><source> Journal of the Royal Statistical Society B</source><volume> 34</volume>,<fpage> 187</fpage>-<lpage>220</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.86068-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Frees, E. (2004) Longitudinal and Panel Data: Analysis and Applications in the Social Sciences. Cambridge University Press, New York.  
https://doi.org/10.1017/CBO9780511790928</mixed-citation></ref><ref id="scirp.86068-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Diggle, P.J., Heagerty, P., Liang, K.-Y. and Zeger, S.L. (2002) Analysis of Longitudinal Data. 2nd Edition, Oxford University Press, Oxford.</mixed-citation></ref><ref id="scirp.86068-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Therneau. T.M. (2015) Mixed Effects Cox Models. BMC Genetics, 6, S127.</mixed-citation></ref><ref id="scirp.86068-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Therneau, T.M. and Grambsch, P.M. (2000) Modeling Survival Data: Extending the Cox Model. Springer, New York. https://doi.org/10.1007/978-1-4757-3294-8</mixed-citation></ref><ref id="scirp.86068-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wooldridge, J.M. (2013) Introductory Econometrics: A Modern Approach. 5th Edition, South-Western, Mason, OH.</mixed-citation></ref><ref id="scirp.86068-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Militino, A.F. (2010) Mixed Effects Models and Extensions in Ecology with R. Journal of Royal Statistical Society, 173, 938-939.  
https://doi.org/10.1111/j.1467-985X.2010.00663_9.x</mixed-citation></ref><ref id="scirp.86068-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Ripatti, S. and Palmgren, J. (2000) Estimation of Multivariate Frailty Models Using Penalized Partial Likelihood. Biometrics, 56, 1016-1022.  
https://doi.org/10.1111/j.0006-341X.2000.01016.x</mixed-citation></ref><ref id="scirp.86068-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Gamst, A., Donohue, M. and Xu, R. (2009) Asymptotic Properties and Empirical Evaluation of the Npmle in the Proportional Hazards Mixed-Effects Model. Statistical Sinica, 19, 997-1011.</mixed-citation></ref></ref-list></back></article>